BONESUPPORT entered into a distribution agreement with OrthoPediatrics to distribute CERAMENT® BONE VOID FILLER (BVF) to pediatric hospitals within the U.S.
In the U.S., CERAMENT BVF is indicated for use in pediatric patients ages nine years and older.
Under the terms of the three-year agreement, OrthoPediatrics will employ its pediatric expertise and infrastructure to promote and distribute CERAMENT BVF within its network of orthopedic pediatric surgeons operating at more than 250 children’s hospitals across the country.
“OrthoPediatrics has demonstrated a strong leadership position in a short period of time, and we are thrilled to enter into this partnership which represents a strategic expansion for CERAMENT into a previously unpenetrated network of hospitals,” said Emil Billbäck, CEO of BONESUPPORT.
“High quality bone graft substitutes are an essential component of orthopedic pediatric procedures. CERAMENT strengthens the OrthoPediatric portfolio, giving our customers access to what we believe is the best bone graft substitute on the market,” said Greg Odle, Executive Vice President of OrthoPediatrics.
BONESUPPORT entered into a distribution agreement with OrthoPediatrics to distribute CERAMENT® BONE VOID FILLER (BVF) to pediatric hospitals within the U.S.
In the U.S., CERAMENT BVF is indicated for use in pediatric patients ages nine years and older.
Under the terms of the three-year agreement, OrthoPediatrics will employ its pediatric...
BONESUPPORT entered into a distribution agreement with OrthoPediatrics to distribute CERAMENT® BONE VOID FILLER (BVF) to pediatric hospitals within the U.S.
In the U.S., CERAMENT BVF is indicated for use in pediatric patients ages nine years and older.
Under the terms of the three-year agreement, OrthoPediatrics will employ its pediatric expertise and infrastructure to promote and distribute CERAMENT BVF within its network of orthopedic pediatric surgeons operating at more than 250 children’s hospitals across the country.
“OrthoPediatrics has demonstrated a strong leadership position in a short period of time, and we are thrilled to enter into this partnership which represents a strategic expansion for CERAMENT into a previously unpenetrated network of hospitals,” said Emil Billbäck, CEO of BONESUPPORT.
“High quality bone graft substitutes are an essential component of orthopedic pediatric procedures. CERAMENT strengthens the OrthoPediatric portfolio, giving our customers access to what we believe is the best bone graft substitute on the market,” said Greg Odle, Executive Vice President of OrthoPediatrics.
Copy to clipboard 
